Clinical Trials
Endometrial Cancer Survival Is An Enhanced Possibility
A Phase III trial found that pembrolizumab plus chemotherapy enhanced survival in endometrial cancer patients.
A Phase III clinical trial comparing pembrolizumab to chemotherapy (carboplatin and paclitaxel) enhanced progression-free survival (PFS) in patients with stage III-IV or recurrent endometrial cancer.
As...
Clinical Trials
Clinical Trials Information System A Must In The EU Now
All initial clinical trial applications across the EU have to be submitted via the Clinical Trials Information System (CTIS) starting January 31, 2023.
As per the European Medicines Agency (EMA), CTIS now happens to be the single-entry point for regulators...
Clinical Trials
Study Suggests Monoclonal Antibodies Good To Fight Malaria
Only one dose of the monoclonal antibody (mAb) CIS43LS gave out high levels of protection against Malaria in challenge study as per new research.
While the previous research that were conducted put out the fact that the monoclonal antibodies...
Clinical Trials
Connect the dots between providers for maximum DCT efficiency
Conducting a decentralized clinical trial (DCT) can sometimes feel like conducting an orchestra. Tracking and connecting the moving parts, siloed service providers, and disparate technology systems can all serve to detract from the model’s stated aim of streamlining clinical...
Clinical Trials
UK- Perfect Destination For Conducting ATMP Clinical Trials
The UK Advanced Therapy Medicinal Products (ATMP) Clinical Trials Report 2022 has been published by Cell and Gene Therapy (CGT).
T cells were said to be the most commonly looked-at cell type in its data. As per the research, this...
Clinical Trials
Update On The Clinical Trials Regulation Implementation
The Clinical Trial Information System went live on January 31, 2022, which began the one-year transition period for all clinical trial sponsors. Clinical trial sponsors are still free to decide whether to submit an initial clinical study application via...
Clinical Trials
CardieX Subsidiary ATCOR Partners with Invaryant to Enable Clinical Trials with Advanced New AI Medical Technology
CardieX Limited, a global health technology company focused on patient-centric healthcare research and improving clinical trial patient outcomes announced a partnership between its ATCOR subsidiary and Invaryant, a data-driven health technology company that empowers individuals with precision AI to...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read